Physician profile
Amanda D Bennett
NPI 1558329862
$1,061.37
in general payments reported to CMS, 2019-2025
21 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $112 · 2023: $379 · 2024: $229 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.53 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $185.08 | 2022-2025 | |
| Novo Nordisk INC | $126.14 | 2021-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $113.25 | 2023-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $108.41 | 2021-2025 | Farxiga |
| Pfizer INC. | $75.82 | 2021-2024 | |
| Exact Sciences Corporation | $62.09 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $55.70 | 2021-2022 | |
| Amarin Pharma, INC. | $40.77 | 2021-2022 | |
| Dexcom, INC. | $39.50 | 2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $30.77 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.79 | 2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $28.54 | 2024 | |
| Alnylam Pharmaceuticals INC. | $27.90 | 2023 | Givlaari |
| Viatris Specialty LLC | $24.92 | 2025 | Yupelri |
| Abbvie INC. | $22.68 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $20.49 | 2024 | Voquezna |
| Exeltis, USA INC. | $17.14 | 2023 | Slynd |
| Mylan Specialty L.P. | $15.32 | 2021 | |
| Glaxosmithkline, LLC. | $13.78 | 2021 | |
| Insulet Corporation | $13.28 | 2023 | Omnipod |
| Endogastric Solutions, INC | $11.00 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.